Sonnet BioTherapeutics Holdings, Inc. (SONN)
Automate Your Wheel Strategy on SONN
With Tiblio's Option Bot, you can configure your own wheel strategy including SONN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SONN
- Rev/Share 0.255
- Book/Share 0.1689
- PB 6.8986
- Debt/Equity 0.1366
- CurrentRatio 1.0265
- ROIC -18.5293
- MktCap 3688169.0
- FreeCF/Share -2.9664
- PFCF -0.317
- PE -0.3439
- Debt/Assets 0.0236
- DivYield 0
- ROE -7.7796
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Sonnet Releases Virtual Investor "What This Means" Segment
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010
Read More
Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose
Published: April 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq ® )
Read More
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Poster presented at the 2025 AACR:IO Conference Company's novel platform that delivers either mono- or bifunctional immunomodulators linked to a Fully-Human, Albumin Binding scFv domain (F H AB ® ) provides enhanced targeting to the tumor microenvironment (TME) and prolonged retention in the tumor PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced the presentation of a compilation of data at the 2025 American Association for Cancer Research (AACR) IO Conference.
Read More
Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Building on proven targeting of the F H AB domain, Sonnet's ADC platform offers flexible payload capacity and controllable drug-antibody ratios (DAR)
Read More
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR)
Read More
About Sonnet BioTherapeutics Holdings, Inc. (SONN)
- IPO Date 2006-10-31
- Website https://www.sonnetbio.com
- Industry Biotechnology
- CEO Mr. Raghu Rao
- Employees 13